Studies of the novel chemotherapeutic drugs for herpesvirus infections

原发性渗出性淋巴瘤（PEL）被分类为与免疫功能低下的患者（例如AIDS患者）相关的非霍奇金B细胞淋巴瘤。PEL细胞普遍感染卡波西肉瘤相关疱疹病毒（KSHV）。以前，我们已经开发了抗肿瘤化合物，CNDAG及其衍生物，诱导细胞凋亡的PEL细胞。为了建立对PEL和KSHV感染的有效治疗，我们已经证明了CNDAG的作用机制和新功能，即抗疱疹病毒活性。我们进一步确定桑戈霉素，富勒烯类似物和丙戊酸钠作为新的抗PEL化合物。

Primary effusion lymphoma (PEL) is classified as non-Hodgkin's B-cell lymphoma associated with immunocompromised patients such as AIDS patients. PEL cells are universally infected with Kaposi's sarcoma-associated herpesvirus (KSHV). Previously, we had developed anti-tumor compounds, CNDAG and its derivatives, which induce apoptosis in PEL cells. To establish the effective treatment for PEL and KSHV infection, we have demonstrated the mechanisms of action of CNDAG and novel functions, namely anti-herpesviral activities. We furthermore identified sangivamycin, fullerene analogues and sodium valproate as new anti-PEL compounds.